arrow_back Civic Audit
Share share

Lower Drug Costs: New Inflation Rebate Rules for Medications

This act aims to reduce drug costs for families by extending inflation rebate rules to drugs sold in the commercial market. It also changes how these rebates are calculated, potentially leading to greater savings for patients and the healthcare system.
Key points
Drug inflation rebates, previously mainly for government programs, will now apply to drugs purchased in the private market.
The base year for calculating inflation rebates has been changed from 2021 to 2016, meaning drug manufacturers will owe larger rebates if their drug prices increase above 2016 levels.
The goal is to lessen the financial burden of medication purchases for citizens.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 118_HR_4115
Sponsor: Rep. Gallego, Ruben [D-AZ-3]
Process start date: 2023-06-14
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Lower Drug Costs for Families Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_4115.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-14.

What are the main provisions?

Key points include:

  • Drug inflation rebates, previously mainly for government programs, will now apply to drugs purchased in the private market.
  • The base year for calculating inflation rebates has been changed from 2021 to 2016, meaning drug manufacturers will owe larger rebates if their drug prices increase above 2016 levels.
  • The goal is to lessen the financial burden of medication purchases for citizens.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Gallego, Ruben [D-AZ-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Economy